AU2020373408A1 - Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure - Google Patents

Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure Download PDF

Info

Publication number
AU2020373408A1
AU2020373408A1 AU2020373408A AU2020373408A AU2020373408A1 AU 2020373408 A1 AU2020373408 A1 AU 2020373408A1 AU 2020373408 A AU2020373408 A AU 2020373408A AU 2020373408 A AU2020373408 A AU 2020373408A AU 2020373408 A1 AU2020373408 A1 AU 2020373408A1
Authority
AU
Australia
Prior art keywords
patient
terlipressin
days
hrs
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020373408A
Other languages
English (en)
Inventor
Khurram Jamil
Stephen Chris Pappas
Peter TEUBER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Hospital Products IP Unlimited Co
Original Assignee
Mallinckrodt Hospital Products IP Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Hospital Products IP Unlimited Co filed Critical Mallinckrodt Hospital Products IP Unlimited Co
Publication of AU2020373408A1 publication Critical patent/AU2020373408A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AU2020373408A 2019-10-30 2020-10-29 Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure Abandoned AU2020373408A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962928152P 2019-10-30 2019-10-30
US62/928,152 2019-10-30
PCT/IB2020/060185 WO2021084483A1 (en) 2019-10-30 2020-10-29 Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure

Publications (1)

Publication Number Publication Date
AU2020373408A1 true AU2020373408A1 (en) 2022-04-21

Family

ID=73060034

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020373408A Abandoned AU2020373408A1 (en) 2019-10-30 2020-10-29 Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure

Country Status (10)

Country Link
US (1) US20210128676A1 (https=)
EP (1) EP4051310A1 (https=)
JP (1) JP2023500654A (https=)
KR (1) KR20220092868A (https=)
CN (1) CN114980914A (https=)
AU (1) AU2020373408A1 (https=)
BR (1) BR112022006329A2 (https=)
CA (1) CA3159575A1 (https=)
MX (1) MX2022004157A (https=)
WO (1) WO2021084483A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240019089A (ko) * 2021-06-07 2024-02-14 말린크로트 파마슈티칼스 아일랜드 리미티드 간신장 증후군 1형 환자의 치료 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015203036A1 (en) * 2010-07-14 2015-07-02 Cumberland Emerging Technologies, Inc Methods of Treating Hepatorenal Syndrom and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists
US10335452B2 (en) * 2014-10-24 2019-07-02 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1

Also Published As

Publication number Publication date
CA3159575A1 (en) 2021-05-06
EP4051310A1 (en) 2022-09-07
US20210128676A1 (en) 2021-05-06
MX2022004157A (es) 2022-07-19
JP2023500654A (ja) 2023-01-10
CN114980914A (zh) 2022-08-30
KR20220092868A (ko) 2022-07-04
BR112022006329A2 (pt) 2022-08-16
WO2021084483A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
JP7346494B2 (ja) １型肝腎症候群患者の治療方法
AU2014256944B2 (en) Compositions and methods for treating renal failure
US20240374675A1 (en) Method of treating patients with hepatorenal syndrome type 1
US20220143132A1 (en) Method of treating patients with hepatorenal syndrome type 1
US20210128676A1 (en) Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure
US20200237856A1 (en) Method of treating patients with hepatorenal syndrome type 1
KR20240019089A (ko) 간신장 증후군 1형 환자의 치료 방법

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period